Is IDXX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The CAG Diagnostics recurring annuity, with revenue (ttm) at ~$4.55B, up ~13% year over year. The bear case rests on visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall. Analysts covering it are spread from $470.00 to $805.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $470.00, -14.7% from the $550.96 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The CAG Diagnostics recurring annuity. CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. The most optimistic analyst target on IDXX is $805.00, +46.1% from the $550.96 price. That figure is only reachable if this thesis works close to its best case.

Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at ~$772 million of net debt against roughly ~$1.7 billion of adjusted EBITDA, but the ~28% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles. The most pessimistic published target is $470.00, -14.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Veterinary diagnostics leader that places analyzers in vet clinics and earns recurring revenue from test consumables and its global reference laboratory network.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The CAG Diagnostics recurring annuity) stalling in the reported numbers rather than in the narrative, the risk above (visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

IDEXX sells diagnostics to veterinary practices. It places blood chemistry, hematology and urinalysis analyzers inside clinics, sells the consumables those instruments use, and runs a global reference laboratory network for tests clinics send out. Smaller Water and Livestock, Poultry and Dairy segments test drinking water and farm animals. Companion animal work is roughly ~92% of revenue.

The analyzer is the razor and the test consumable is the blade. IDEXX places Catalyst, ProCyte, SediVue and inVue Dx instruments into practices at modest instrument revenue, then earns for years on slides, cartridges and reagents. Capital instrument sales fell ~20% in Q2 2026 while the recurring consumable and laboratory revenue they generate grew ~11%, which is the intended shape.

CAG Diagnostics recurring revenue was ~$975 million of ~$1.22 billion in total Q2 2026 revenue, about ~80%. Add recurring veterinary software revenue of ~$76 million and the share of the quarter that repeats rises to roughly ~86%. Capital instrument sales were only ~$47 million, or about ~4% of the quarter.